Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts
Portfolio Pulse from Benzinga Insights
Fusion Pharmaceuticals (NASDAQ:FUSN) has received mixed evaluations from 6 analysts in the past three months, with recent sentiment slightly less bullish than the previous month. The average 12-month price target for FUSN is now $14.00, up from $13.25, with a high estimate of $16.00 and a low of $12.00. Analysts from Wedbush, Raymond James, Oppenheimer, and RBC Capital have provided ratings and adjusted price targets, reflecting their views on the company's performance and market conditions. Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for cancer. Despite a significant revenue growth rate of 1108.43% as of September 30, 2023, the company's financial health indicators such as net margin and ROE are below industry standards, although it has a low debt-to-equity ratio.
January 26, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed opinions on FUSN, with recent price target adjustments and an average 12-month target of $14.00. The company shows strong revenue growth but has financial health concerns.
The mixed analyst ratings and the slight increase in the average price target suggest a neutral short-term impact on FUSN's stock price. The strong revenue growth is positive, but concerns about net margin and ROE may temper investor enthusiasm. The high relevance is due to the direct mention of FUSN and detailed analyst ratings. The importance is high because analyst ratings can influence investor sentiment, but not at the maximum because the ratings are mixed. The confidence level is high due to the clear data provided but not at the maximum due to the inherent uncertainty in analyst predictions.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100